ZURA
Zura Bio Ltd - Ordinary Shares - Class A

1,100
Mkt Cap
$474.23M
Volume
1.2M
52W High
$7.44
52W Low
$0.97
PE Ratio
-4.61
ZURA Fundamentals
Price
$5.50
Prev Close
$6.12
Open
$5.85
50D MA
$6.16
Beta
1.27
Avg. Volume
516,660.49
EPS (Annual)
-$1.06
P/B
3.99
Rev/Employee
$0.00
$383.99
Loading...
Loading...
News
all
press releases
Zura Bio (NASDAQ:ZURA) Given New $15.00 Price Target at Oppenheimer
Oppenheimer lowered their target price on shares of Zura Bio from $16.00 to $15.00 and set an "outperform" rating for the company in a research note on Friday...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Zura Bio Limited (NASDAQ:ZURA) Given Average Recommendation of "Moderate Buy" by Analysts
Zura Bio Limited (NASDAQ:ZURA - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven research firms that are currently covering the stock, Marketbeat Ratings...
MarketBeat·2d ago
News Placeholder
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates
Zura Bio Limited (Nasdaq: ZURA) (Zura), a clinicalstage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating...
Business Wire·2d ago
News Placeholder
Boothbay Fund Management LLC Acquires New Shares in Zura Bio Limited $ZURA
Boothbay Fund Management LLC acquired a new position in shares of Zura Bio Limited (NASDAQ:ZURA - Free Report) during the third quarter, according to the company in its most recent Form 13F filing...
MarketBeat·5d ago
News Placeholder
Zura Bio Limited (NASDAQ:ZURA) Short Interest Up 16.2% in February
Zura Bio Limited (NASDAQ:ZURA - Get Free Report) was the recipient of a significant increase in short interest during the month of February. As of February 27th, there was short interest totaling...
MarketBeat·5d ago
News Placeholder
Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress
Zura Bio Limited (Nasdaq: ZURA) (Zura), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and...
Business Wire·17d ago
News Placeholder
Insider Buying: Zura Bio (NASDAQ:ZURA) Major Shareholder Purchases 2,000,000 Shares of Stock
Zura Bio Limited (NASDAQ:ZURA - Get Free Report) major shareholder Ai Biotechnology Llc bought 2,000,000 shares of the business's stock in a transaction on Thursday, February 26th. The stock was...
MarketBeat·19d ago
News Placeholder
Zura Bio to Participate in Upcoming Investor Conferences
Zura Bio Limited (Nasdaq: ZURA) (Zura or the Company), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious...
Business Wire·20d ago
News Placeholder
Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares
Zura Bio Limited (Nasdaq: ZURA) (Zura), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and...
Business Wire·23d ago
News Placeholder
Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
Zura Bio Limited (Nasdaq: ZURA), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating...
Business Wire·25d ago
<
1
2
...
>

Latest ZURA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.